Eplerenone suppresses salt-induced vascular endothelial growth factor expression in the kidney

Kidney and Blood Pressure Research

Volumn 33, Issue 3, 2010, Pages 167-173

  Eatman, Danita ^a   Layas, Mohammed F ^a   Bayorh, Mohamed A ^a  

^a MOREHOUSE SCHOOL OF MEDICINE   (United States)

Author keywords

Dahl rat; Hypertension; Mineralcorticoid receptor antagonist; Nitric oxide synthase

Indexed keywords

ENALAPRIL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EPLERENONE; MESSENGER RNA; SODIUM CHLORIDE; VASCULOTROPIN; MINERALOCORTICOID ANTAGONIST; SPIRONOLACTONE; VASCULAR ENDOTHELIAL GROWTH FACTOR A, RAT; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; GLOMERULOSCLEROSIS; KIDNEY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SALT INTAKE; SYSTOLIC BLOOD PRESSURE; TISSUE INJURY; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BLOOD PRESSURE; DAHL RAT; DRUG EFFECTS; GENE EXPRESSION REGULATION; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ANIMALS; BLOOD PRESSURE; GENE EXPRESSION REGULATION; KIDNEY; MALE; MINERALOCORTICOID RECEPTOR ANTAGONISTS; RATS; RATS, INBRED DAHL; SPIRONOLACTONE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77953661700     PISSN: 14204096     EISSN: None     Source Type: Journal    
DOI: 10.1159/000316700     Document Type: Article

References (40)

1. Sanders PW: Salt intake, endothelial cell signaling, and progression of kidney disease. Hypertension 2004; 43: 142-146.
2. Bayorh MA, Ganafa AA, Emmett N, Socci RR, Eatman D, Fridie IL: Alterations in aldosterone and angiotensin II levels in salt-induced hypertension. Clin Exp Hypertens 2005; 4: 355-367.
3. Cachofeiro V, Miana M, de Las Heras N, Martin-Fernandez B, Ballesteros S, Fernandez-Tresguerres J, Lahera V: Aldosterone and the vascular system. J Steroid Biochem Mol Biol 2008; 109: 331-335.
4. Cortinovis M, Perico N, Cattaneo D, Remuzzi G: Aldosterone and progression of kidney disease. Ther Adv Cardiovasc Dis 2009; 3: 133.
5. Martinez DV, Rocha R, Matsumura M, Oestreicher E, Ochoa-Maya M, Roubsanthisuk W, Williams GH, Adler GK: Cardiac damage prevention by eplerenone: comparison with low sodium diet or potassium loading. Hypertension 2002; 39: 614-618.
6. McMahon EG: Recent studies with eplerenone, a novel selective aldosterone receptor antagonist. Curr Opin Pharmacol 2001; 1: 190-196.
7. Rocha R, Rudolph AE, Frierdich GE, Nachowiak DA, Kekec BK, Blomme EA, McMahon EG, Delyani JA: Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol 2002; 283:H1802-H1810.
8. Rocha R, Stier CT Jr, Kifor I, Ochoa-Maya MR, Rennke H, Williams GH, Adler GK: Aldosterone: a mediator of myocardial necrosis and renal injury. Endocrinology 2000; 141: 3871-3878.
9. Rocha R, Chander PN, Zuckerman A, Stier CT: Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension 1999; 33: 232-237.
10. Belgore FM, Blann AD, Li-Saw-Hee FL, Beevers DG, Lip GYH: Plasma levels of vascular endothelial growth factor and its soluble receptor (SFlt-1) in essential hypertension. Am J Cardiol 2001; 87: 805-807.
11. Murohara T, Horrowitz JR, Silver M, Tsurumi Y, Chen D, Sullivan A, Isner, JM: Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin. Circulation 1998; 97: 99-107.
12. Zachary I, Mathur A, Yla-Herttuala S, Martin J: Vascular protection: a novel nonangiogenic cardiovascular role for vascular endothelial growth factor. Arterioscler Thromb Vasc Biol 2000; 20: 1512-1520.
13. Nadar SK, Blann A, Beevers DG, Lip GYH: Abnormal angiopoietins 1 and 2, angiopoietin receptor Tie-2 and vascular endothelial growth factor levels in hypertension: relationship to target organ damage. A substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). J Intern Med 2005; 258: 336-343.
14. Bayorh MA, Mann G, Walton M, Eatman D: Effects of enalapril, tempol, and eplerenone on salt-induced hypertension in Dahl saltsensitive rats. Clin Exp Hypertens 2006; 28: 121-132.
15. Catanzaro DF, Kurtz TW: Target organ damage in hypertension: mechanisms, prevention, and management. Am J Hypertens 2002; 15: 1117-1118.
16. Rajagopalan S, Duquaine D, King S, Pitt B, Patel P: Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation 2002; 105: 2212-2216.
17. Virdis A, Neves MF, Amiri F, Viel E, Touyz RM, Schiffrin EL: Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension 2002; 40: 504-510.
18. Stier CT Jr, Benter IF, Ahmad S, Zuo H, Selig N, Roethel S, Levine S, Itskovitz HD: Enalapril prevents stroke and kidney dysfunction in salt-loaded stroke-prone spontaneously hypertensive rats. Hypertension 1989; 13: 115-121.
19. Ruggenenti P, Bettinaglio P, Pinares F, Remuzzi G: Angiotensin-converting enzyme insertion/deletion polymorphism and renoprotection in diabetic and nondiabetic nephropathies. Clin J Am Soc Nephrol 2008; 3: 1511-1525.
20. Ruggenenti P, Perna A, Loriga G, Ganeva M, Ene-Iordache B, Turturro M, Lesti M, Perticucci E, Nediyalkov I, Leonardis D, Garini G, Sessa A, Basile C, Alpa M, Scanziani R, Sorba G, Zoccali C, Remuzzi G: Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre randomized controlled trial. Lancet 2005; 365: 939-946.
21. Keane WF, Zhang Z, Lyle PA, Cooper ME, de Zeeuw D, Grunfeld JP, et al: Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study. Clin J Am Soc Nephrol 2006; 1: 761-767.
22. Remuzzi G, Macia M, Ruggenenti P: Prevention and treatment of diabetic renal disease in type 2 diabetes: the BENEDICT study. J Am Soc Nephrol 2006; 17:S90-S97.
23. Rocha R, Martin-Berger CL, Yang P, Scherrer R, Delyani JA, MacMahon EG: Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. Endocrinology 2002; 43: 4828-4836.
24. Nagase M, Shibata S, Yoshida S, Nagase T, Gotoda T, Fujita T: Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker. Hypertension 2006; 47: 1084-1093.
25. Aldigier JC, Kanjanbuch T, Ma L, Brown NJ, Fogo AB: Regression of existing glomerulosclerosis by inhibition of aldosterone. Am Soc Nephrol 2005; 16: 3306-3314.
26. Kroll J, Waltenberger J: A novel function of the vascular endothelial growth factor receptor-2 (KDR): rapid release of nitric oxide in response to VEGF-A stimulation in endothelial cells. Biochem Biophys Res Commun 1999; 265: 636-639.
27. Mechtcherriakova D, Wlachos A, Holzmuller H, Binder BR, Hofer E: Vascular endothelial growth factor-induced tissue factor expression in endothelial cells. Blood 1999; 93: 3811-3823.
28. Foster RR: The importance of cellular VEGF bioactivity in the development of glomerular disease. Nephron Exp Nephrol 2009; 113:e8-e15.
29. Tsai WC, Li YH, Huang YY, Lin CC, Chao TH, Chen JH: Plasma vascular endothelial growth factor as a marker for early vascular damage in hypertension. Clin Sci 2005; 109: 39-43.
30. Ferrara N, Davis-Smyth T: The biology of vascular endothelial growth factor. Endocr Rev 1997; 18: 14-25.
31. Kroll J, Waltenberger J: VEGF-A induces expression of eNOS and iNOS in endothelial cells via VEGF receptor-2. Biochem Biophys Res Commun 1998; 252: 743-746.
32. Hood JD, Meininger CJ, Ziche M, Granger HJ: VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol 1998; 274:H1054-H1058.
33. Shen B-Q, Lee DY, Zioncheck TF: Vascular endothelial growth factor governs endothelial nitric-oxide synthase expression via a KDR/Flk-1 receptor and protein kinase C signaling pathway. J Biol Chem 1999; 274: 33057-33063.
34. Dembinska-Kiec A, Dulak J, Partyka L, Huk I, Mailnski T: VEGF nitric oxide reciprocal regulation. Nat Med 1997; 11: 1177.
35. Tsumuri Y, Murohara T, Krasinski K, Chen D, Witzenbichler B, Kearney M, Couffinhal T, Isner JM: Reciprocal relation between VEGF and NO in the regulation of endothelial integrity. Nat Med 1997; 8: 879-886.
36. Ghiso N, Rohan RM, Amano S, Garland R, Adamis AP: Suppression of hypoxia-associated vascular endothelial growth factor gene expression by nitric oxide via cGMP. Invest Ophthalmol Vis Sci 1999; 40: 1033-1039.
37. Stuhlmeier KM: Activation and regulation of Hsp32 and Hsp70. Eur J Biochem 2000; 267: 1161-1167.
38. Li GC, Li LG, Liu YK, Mak JY, Chen LL, Lee WM: Thermal response of rat fibroblast stably transfected with the human 70-kDa heat shock protein-encoding gene. Proc Natl Acad Sci USA 1991; 88: 1681-1685.
39. Morimoto RI, Tissieres A, Georgopoulos C: Progress and perspectives on the biology of heat shock proteins and molecular chaperones; in Morimoto RI, Tissieres A, Georgopoulos C (eds): The Biology of Heat Shock Proteins and Molecular Chaperones. Cold Spring Harbor, Cold Spring Harbor Laboratory Press, 1994, pp 1-30.
40. Tazi KA, Barrière E, Moreau R, Heller J, Sogni P, Pateron D, Poirel O, Lebrec D: Role of shear stress in aortic eNOS upregulation in rats with biliary cirrhosis. Gastroenterology 2002; 122: 1869-1877.